Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.

Thorac Cancer · 2021 · PMC7952794 · PMID 33527756

Europe PMC DOI

hedged sentences

0.1003

closest p · 2.0× alpha

0.1003

boldest claim

The sentences

a nonsignificant trendp = 0.1003not close (p > 0.1)

On the contrary, a nonsignificant trend towards a reduced risk of disease progression (HR = 0.74 [95% CI: 0.52–1.05], p = 0.1003) and death (HR = 0.67 [95% CI: 0.45–1.01], p = 0.0593) were reported for never smokers within the chemotherapy cohort.

also in 5,406 other papers

a significant trendno p-value reported

22 Concordantly, we previously reported a significant trend towards an increased PD‐L1 expression according to the smoking status (never, former and current smokers) within our study population. 6 In the context of single‐agent pembrolizumab, current/former smokers have already been confirmed to experience improved ORR and prolonged survival within th

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.